The Cooper Companies, Inc. (COO) Stock: Price, Forecast & Analyst Target
The Cooper Companies, Inc. (COO) — MoonshotScore 39/100 (Weak band), calculated Oct 4, 2026. Price $56.91 (-0.87%), as of the Oct 2, 2026 trading session; market cap $11.1B. Expected results Dec 3, 2026.
Listing-status flag — 8-K Item 3.01, filed Sep 12, 2023.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 71.75× (market value Oct 2, 2026; cash Jul 31, 2026) · expected results Dec 3, 2026
The Cooper Companies, Inc. · COO · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Cooper combines contact lenses with women’s and fertility health products, with CooperVision contributing the larger share of revenue. The case hinges on whether lens growth can regain momentum while CooperSurgical expands and cash generation carries a debt load far above cash.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · The Cooper Companies (COO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a cheap price — and it’s docked well below the pillars; verify the gap before trusting the setup. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $1.07B (Q3 FY2026, quarter ended Jul 2026)
- EPS beat 7 of 8
- Altman Z 2.94 · Piotroski F 7
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak |
The score was 39 in the stored Oct 3, 2026 snapshot and remains 39 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $56.91 |
| Change on the day | -0.87% |
| 52-week range | $51.01–$89.83 |
| Market capitalisation | $11.1B |
| Price / earnings (trailing) | 19.42 |
| Shares traded on the day | 3.31M |
| Beta (volatility vs the S&P 500) | 0.82 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Looking ahead, we expect MiSight growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027, supported by continued momentum in existing markets and the upcoming launch of MyDay MiSight toric.
Albert White · Statement from
For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. We expect CooperVision revenue of $692 million to $706 million, down 2% to flat organically.
Brian Andrews · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for The Cooper Companies (COO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the COO film — every key number, told as a short cinematic story
~2 min · open the film
What is The Cooper Companies (COO), and what does it report?
Short answer · as of
CooperVision sells spherical, toric, multifocal and specialty contact lenses for needs ranging from astigmatism and presbyopia to myopia and dry eyes.
Research dated 2026-09-13.
CooperVision sells spherical, toric, multifocal and specialty contact lenses for needs ranging from astigmatism and presbyopia to myopia and dry eyes. CooperSurgical serves women’s and family health through clinical devices, fertility consumables and services, genetic testing, diagnostics and contraception.
Consolidated revenue therefore blends lens purchases across global markets with demand from fertility clinics and other healthcare providers. CooperVision supplies the larger revenue base, so contact-lens performance has greater influence on the reported top line even though CooperSurgical broadens the business beyond vision correction.
What do the latest results show for The Cooper Companies (COO)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.07B.
Research dated 2026-09-13.
Revenue eased from the prior period, while operating profit and net income swung sharply positive after a loss. Revenue missed consensus even as the reported earnings measure exceeded expectations, so the profit rebound was materially stronger than the sales trend.
Management attributes near-term CooperVision weakness to channel inventory actions in the Americas and continued challenges in Asia Pacific, while describing Europe, the Middle East and Africa as resilient. Its outlook pairs muted vision performance with continued organic growth at CooperSurgical and sustained MiSight momentum despite a difficult comparison.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.07B Jul 31, 2026
- Latest quarter · R&D
- $41.60M Jul 31, 2026
- Latest quarter · SG&A
- $401.30M Jul 31, 2026
- Latest quarter · FMP standardized operating result
- $222.40M Jul 31, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | $1.07B | $41.60M | $401.30M | $222.40M |
| Apr 30, 2026 | $1.08B | $42.50M | $676.20M | −$31.00M |
| Jan 31, 2026 | $1.02B | $44.30M | $390.20M | $212.80M |
| Oct 31, 2025 | $1.07B | $41.40M | $419.20M | $140.40M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.07B Sep 9, 2026
- Latest report · revenue estimate
- $1.10B Sep 9, 2026
- Latest report · revenue vs estimate
- Below estimate Sep 9, 2026
- Latest report · EPS vs estimate
- Above estimate Sep 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 9, 2026 | $1.07B | $1.10B | $1.1500 | $1.1200 |
| Jun 4, 2026 | $1.08B | $1.05B | $1.2100 | $1.1000 |
| Mar 5, 2026 | $1.02B | $1.02B | $1.1000 | $1.0300 |
| Dec 4, 2025 | $1.07B | $1.06B | $1.1500 | $1.1100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.07B | $433M | $2.24 (diluted) |
| Q2 FY2026 | $1.08B | -$78M | -$0.40 (diluted) |
| Q1 FY2026 | $1.02B | $131M | $0.66 (diluted) |
| Q4 FY2025 | $1.07B | $85M | $0.43 (diluted) |
What are the financial strengths and risks for The Cooper Companies (COO)?
Short answer
Cash and short-term investments were $154.70M at the Jul 31, 2026 balance-sheet date. Operating cash flow was $341.70M for the quarter ended Jul 31, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has remained positive throughout the displayed history, and the cash balance has risen across recent periods. Current assets cover current liabilities, but quick assets do not; cash also remains small beside total debt, while the trailing free-cash-flow yield is thin.
Annual revenue has advanced, but net income has moved unevenly even as research and development spending climbed. A prolonged CooperVision slowdown would matter disproportionately because that segment supplies most revenue, and weaker cash conversion would leave less flexibility against the debt burden.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $341.70M Jul 31, 2026
- Previous quarter · operating cash flow
- $182.80M Apr 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 31, 2026 | $341.70M | −$68.70M |
| Apr 30, 2026 | $182.80M | −$86.40M |
| Jan 31, 2026 | $260.90M | −$102.20M |
| Oct 31, 2025 | $247.90M | −$98.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at The Cooper Companies (COO)?
Short answer · as of
The next earnings report is expected on Dec 3, 2026.
Research dated 2026-09-13.
Americas lens sales are the immediate operational tell. Stabilization would support management’s view that channel inventory actions are a near-term drag, while continued weakness would make that explanation less reassuring; the contrast between resilient European markets and challenged Asia Pacific markets deserves the same scrutiny.
MiSight growth and the MyDay MiSight toric rollout will show whether CooperVision can create product momentum despite softer regional demand. At CooperSurgical, sustained organic growth would demonstrate that the smaller business can offset some vision weakness.
Compare revenue with consensus alongside earnings at the scheduled report. Recent releases have repeatedly exceeded earnings expectations, but revenue has not cleared expectations consistently, making top-line delivery the cleaner confirmation of renewed operating momentum.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Looking ahead, we expect MiSight growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027, supported by continued momentum in existing markets and the upcoming launch of MyDay MiSight toric.
Albert White ·
For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. We expect CooperVision revenue of $692 million to $706 million, down 2% to flat organically.
Brian Andrews ·
Within this, we expect regional performance trends to be broadly consistent with Q3, with the Americas reflecting the impact of channel inventory actions, EMEA delivering another solid quarter and Asia Pac continuing to face near-term challenges. We expect CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%.
Brian Andrews ·
Finally, while the strategic review process was extremely challenging for our teams, it provided valuable insights, and we believe we are well positioned to execute our plans and deliver strong performance in 2027 and beyond.
Albert White ·
How does The Cooper Companies compare with its peers?
Short answer
The Cooper Companies's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Relative to a business concentrated solely in contact lenses or fertility products, Cooper joins distinct demand engines under one company. Lens purchases depend on vision-correction demand, product mix and distributor ordering, while CooperSurgical participates in clinical procedures, fertility workflows, genetic testing and contraception.
Cooper is not simply a capital-equipment manufacturer: its offering spans lenses, consumables, devices and services. That breadth can produce different growth patterns within the same reporting period, although the larger CooperVision base keeps contact-lens execution more influential for consolidated results.
| Company | Price | Market value | Score |
|---|---|---|---|
| $364.98 Oct 2, 2026 | $25.7B | 93 5-pillar Oct 4, 2026 | |
| $143.18 Oct 2, 2026 | $14.4B | 90 5-pillar Oct 4, 2026 | |
| $104.68 Oct 2, 2026 | $4.76B | 88 5-pillar Oct 4, 2026 | |
| $26.42 Oct 2, 2026 | $11.1B | 87 5-pillar Oct 4, 2026 | |
| $85.37 Oct 2, 2026 | $5.10B | 86 5-pillar Oct 4, 2026 | |
| $22.25 Oct 2, 2026 | $12.0B | 84 5-pillar Oct 4, 2026 | |
| $181.70 Oct 2, 2026 | $10.3B | 82 5-pillar Oct 4, 2026 | |
| $20.20 Oct 2, 2026 | $5.51B | 80 5-pillar Oct 4, 2026 | |
| $119.91 Oct 2, 2026 | $7.65B | 76 5-pillar Oct 4, 2026 | |
| $15.34 Oct 2, 2026 | $10.4B | 56 5-pillar Oct 4, 2026 | |
| $124.12 Oct 2, 2026 | $5.49B | 55 5-pillar Oct 4, 2026 | |
| $23.49 Oct 2, 2026 | $12.1B | 53 5-pillar Oct 4, 2026 | |
| The Cooper Companies (COO) — this page | $56.91 | $11.1B | 39 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $59.00 – $75.00
- Consensus target
- $65.75
- Median target
- $63.50
Consensus record · Captured .
Measured against a quoted price of $56.91 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 16, 2026
- Transactions
- 6
- Identified insiders
- 3
- Purchases
- 5
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 684 Period end Jun 30, 2026
- Previous quarter · holders
- 682 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 15,029,453 |
| Vanguard Capital Management LLC | 12,758,769 |
| State Street Corp | 8,892,643 |
| Vanguard Portfolio Management LLC | 8,669,690 |
| T. Rowe Price Investment Management, INC. | 7,429,535 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about The Cooper Companies (COO)?
- Securities Fraud Investigation Into The Cooper Companies, Inc. (COO) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
The Cooper Companies Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why can CooperVision weaken even when patients still need contact lenses?
Management points to channel inventory actions in the Americas, so reported sales can reflect distributor ordering as well as patient demand. Regional performance also differs, with resilience in European markets alongside pressure in Asia Pacific.
How does CooperSurgical change the Cooper business mix?
CooperSurgical adds women’s health devices, fertility consumables and services, genetic testing, diagnostics and contraception to a company otherwise led by contact lenses. It is the smaller segment, but management expects it to grow while CooperVision faces near-term pressure.
What matters in the MyDay MiSight toric launch?
The rollout matters because it extends the MiSight franchise into toric lenses while management is seeking continued myopia-product momentum. Adoption would provide a product-specific counterweight to channel and regional pressure within CooperVision.
Why did Cooper’s latest profit rebound look stronger than its revenue trend?
Selling, general and administrative expense fell sharply from the prior period, coinciding with a return to operating profit even as revenue eased. The divergence makes expense discipline and the repeatability of the profit improvement important checks.
What is the COO stock price today?
The last price recorded on this page for The Cooper Companies, Inc. (COO) is $56.91, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the COO price target?
The analyst consensus price target for The Cooper Companies, Inc. (COO) is $65.75 (range $59.00 to $75.00, median $63.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (82 figures)
The 82 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 3 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
list.rule_notice | Listing-status notice (8-K Item 3.01) | 8-K Item 3.01, filed Sep 12, 2023 | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — Item 3.01 covers both continued-listing notices and voluntary transfers between exchanges; the filing states which applies and any cure terms. | |
prod.outlook | Management outlook — call excerpts | Albert White (Sep 9, 2026): Looking ahead, we expect MiSight growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027, supported by continued momentum in existing markets and the upcoming launch of MyDay MiSight toric. Brian Andrews (Sep 9, 2026): For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. We expect CooperVision revenue of $692 million to $706 million, down 2% to flat organically. Brian Andrews (Sep 9, 2026): Within this, we expect regional performance trends to be broadly consistent with Q3, with the Americas reflecting the impact of channel inventory actions, EMEA delivering another solid quarter and Asia Pac continuing to face near-term challenges. We expect CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%. Albert White (Sep 9, 2026): Finally, while the strategic review process was extremely challenging for our teams, it provided valuable insights, and we believe we are well positioned to execute our plans and deliver strong performance in 2027 and beyond. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 6101 Bollinger Canyon Road, Suite 500, SAN Ramon, CA, 94583 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "6101 Bollinger Canyon Road, San Ramon, CA, 94583, US". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Dec 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $56.91 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:38.342Z. | |
px.change | Change on the day | -0.87% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $11.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:37.404Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.50 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $1.07B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $51.01–$89.83 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 19.42 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.31M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.82 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Albert G. White | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 15,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $2.92B, net result $2.94B; FY2022 revenue $3.31B, net result $385.80M; FY2023 revenue $3.59B, net result $294.20M; FY2024 revenue $3.90B, net result $392.30M; FY2025 revenue $4.09B, net result $374.90M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Coopervision Segment $2.74B · Coopersurgical Segment $1.35B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 63.6% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-31.revenue_k | Revenue — period end 2026-07-31 | $1.07B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.rd_k | R&D — period end 2026-07-31 | $41.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.sga_k | SG&A — period end 2026-07-31 | $401.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.operating_result_k | FMP standardized operating result — period end 2026-07-31 | $222.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-30.revenue_k | Revenue — period end 2026-04-30 | $1.08B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-30.rd_k | R&D — period end 2026-04-30 | $42.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-30.sga_k | SG&A — period end 2026-04-30 | $676.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-30.operating_result_k | FMP standardized operating result — period end 2026-04-30 | −$31.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.revenue_k | Revenue — period end 2026-01-31 | $1.02B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.rd_k | R&D — period end 2026-01-31 | $44.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.sga_k | SG&A — period end 2026-01-31 | $390.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.operating_result_k | FMP standardized operating result — period end 2026-01-31 | $212.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.revenue_k | Revenue — period end 2025-10-31 | $1.07B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.rd_k | R&D — period end 2025-10-31 | $41.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.sga_k | SG&A — period end 2025-10-31 | $419.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.operating_result_k | FMP standardized operating result — period end 2025-10-31 | $140.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-09-09.revenue_actual | Revenue · reported — report date 2026-09-09 | $1.07B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-09.revenue_estimated | Revenue · estimate — report date 2026-09-09 | $1.10B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-09.eps_actual | EPS · reported — report date 2026-09-09 | $1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-09.eps_estimated | EPS · estimate — report date 2026-09-09 | $1.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-04.revenue_actual | Revenue · reported — report date 2026-06-04 | $1.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-04.revenue_estimated | Revenue · estimate — report date 2026-06-04 | $1.05B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-04.eps_actual | EPS · reported — report date 2026-06-04 | $1.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-04.eps_estimated | EPS · estimate — report date 2026-06-04 | $1.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.revenue_actual | Revenue · reported — report date 2026-03-05 | $1.02B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.revenue_estimated | Revenue · estimate — report date 2026-03-05 | $1.02B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.eps_actual | EPS · reported — report date 2026-03-05 | $1.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.eps_estimated | EPS · estimate — report date 2026-03-05 | $1.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-04.revenue_actual | Revenue · reported — report date 2025-12-04 | $1.07B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-04.revenue_estimated | Revenue · estimate — report date 2025-12-04 | $1.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-04.eps_actual | EPS · reported — report date 2025-12-04 | $1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-04.eps_estimated | EPS · estimate — report date 2025-12-04 | $1.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $154.70M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $341.70M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-31. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $2.54B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.32× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-31.operating_cash_flow_m | Operating cash flow — period end 2026-07-31 | $341.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-30.operating_cash_flow_m | Operating cash flow — period end 2026-04-30 | $182.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-31.capex_m | Capital expenditure (reported) — period end 2026-07-31 | −$68.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-30.capex_m | Capital expenditure (reported) — period end 2026-04-30 | −$86.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-31.operating_cash_flow_m | Operating cash flow — period end 2026-01-31 | $260.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-31.capex_m | Capital expenditure (reported) — period end 2026-01-31 | −$102.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-31.operating_cash_flow_m | Operating cash flow — period end 2025-10-31 | $247.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-31.capex_m | Capital expenditure (reported) — period end 2025-10-31 | −$98.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $59.00 – $75.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $65.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $63.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 6 transactions · 5 purchases, 0 sales, 1 other transactions · 3 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 16, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 684 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 682 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 15,029,453 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 12,758,769 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 8,892,643 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 8,669,690 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 7,429,535 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.94 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 71.75× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $154.70M at Jul 31, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-07-31. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-09-09.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.07B) with the recorded estimate ($1.10B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-09-09.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.1500) with the recorded estimate ($1.1200) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 39 of 100 · Weak · pillars 83 / 56 / 74 / 85 / 42 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 39 (stored snapshot Oct 3, 2026) → 39 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-31. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-31.revenue_k,fin.q_table.depth.2026-07-31.rd_k,fin.q_table.depth.2026-07-31.sga_k,fin.q_table.depth.2026-07-31.operating_result_k,fin.q_table.depth.2026-04-30.revenue_k,fin.q_table.depth.2026-04-30.rd_k,fin.q_table.depth.2026-04-30.sga_k,fin.q_table.depth.2026-04-30.operating_result_k,fin.q_table.depth.2026-01-31.revenue_k,fin.q_table.depth.2026-01-31.rd_k,fin.q_table.depth.2026-01-31.sga_k,fin.q_table.depth.2026-01-31.operating_result_k,fin.q_table.depth.2025-10-31.revenue_k,fin.q_table.depth.2025-10-31.rd_k,fin.q_table.depth.2025-10-31.sga_k,fin.q_table.depth.2025-10-31.operating_result_k. - Earnings-history note. Source series as of 2026-09-09. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-09-09.revenue_actual,earn.history.depth.2026-09-09.revenue_estimated,earn.history.depth.2026-09-09.revenue_actual.comparison,earn.history.depth.2026-09-09.eps_actual.comparison,earn.history.depth.2026-09-09.eps_actual,earn.history.depth.2026-09-09.eps_estimated,earn.history.depth.2026-06-04.revenue_actual,earn.history.depth.2026-06-04.revenue_estimated,earn.history.depth.2026-06-04.eps_actual,earn.history.depth.2026-06-04.eps_estimated,earn.history.depth.2026-03-05.revenue_actual,earn.history.depth.2026-03-05.revenue_estimated,earn.history.depth.2026-03-05.eps_actual,earn.history.depth.2026-03-05.eps_estimated,earn.history.depth.2025-12-04.revenue_actual,earn.history.depth.2025-12-04.revenue_estimated,earn.history.depth.2025-12-04.eps_actual,earn.history.depth.2025-12-04.eps_estimated. - Cash-flow note. Source series as of 2026-07-31. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-31.operating_cash_flow_m,fin.opcf.depth.2026-04-30.operating_cash_flow_m,fin.opcf.depth.2026-07-31.capex_m,fin.opcf.depth.2026-04-30.capex_m,fin.opcf.depth.2026-01-31.operating_cash_flow_m,fin.opcf.depth.2026-01-31.capex_m,fin.opcf.depth.2025-10-31.operating_cash_flow_m,fin.opcf.depth.2025-10-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Coopervision Segment: $2.74B; Coopersurgical Segment: $1.35B | 2025-10-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Cash, investments and debt | Total debt: $2.54B; Liquidity basis: cash and short-term investments; Total liabilities: $4.34B; Cash and short-term investments: $154.70M; Cash and investments: $154.70M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-09-09 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Instruments & Supplies The company's SEC filings classify it under SIC 3851 — Ophthalmic Goods. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-09-09 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $154.70M; Cash and short-term investments: $154.70M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-07-31 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-07-31; Cash basis: cash and short-term investments; Net cash: -$2.39B; Total debt: $2.54B; Cash and investments: $154.70M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-07-31 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.73; Current ratio: 1.22; Debt to equity: 0.31; Net margin: 13.5%; Gross margin: 63.6%; Operating margin: 12.9%; Return on assets: 4.5%; Return on equity: 6.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-10-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Next earnings report | Date: 2026-12-03; EPS estimate: $1.11 per share; Revenue estimate: $1.07B The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.